About Lapam Capital
Lapam Capital is a venture capital firm founded in 2011. It is primarily based out of Beijing, China. As of May 2026, Lapam Capital is an active investor, having invested in 19 companies, with 6 new investments in the last 12 months. It primarily invests in Series A round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series A round of Degron Therapeutics Overall, Lapam Capital portfolio has seen 1 IPO, namely Suzhou Connect Biopharmaceuticals. A lot of funds co-invest with Lapam Capital, with names like Deyi Capital sharing a substantial percentage of its portfolio. Lapam Capital has team of 1 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 2 more
Portfolio IPOs
Portfolio Soonicorns
Deals in last 12 months
Lapam Capital's List of Top Investments
Lapam Capital has a portfolio of 19 companies. Their most notable investments are in ReviR Therapeutics and BridGene Biosciences.Their portfolio spans across China and United States. They have invested in Life Sciences, High Tech, HealthTech and 1 other sectors, across stages such as Series A, Series B and 2 more. Here is the list of top investments by Lapam Capital:
Provider of discovery, development, production, and logistics services for of nuclear medicines. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals. It manufactures radiopharmaceutical drug products.
Key facts about Full-Life Technologies
- Founded Year: 2021
- Location: Shanghai (China)
- Stage: Series D
- Total Funding till date: $350M
- Employee Count: 65 as on May 31, 2026
- Investors: Prosperity7 Ventures, Summer Capital and 18 Others
- Latest Funding Round: Series D, May 18, 2026, $*****
Developer of immunotherapies to treat cancer and other diseases. The company focuses on the development of immunotherapies that are capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science technology.
Key facts about LTZ Therapeutics
- Founded Year: 2021
- Location: Redwood City (United States)
- Stage: Series B
- Total Funding till date: $85M
- Employee Count: 43 as on May 31, 2026
- Investors: Shunwei Capital, Tigermed and 7 Others
- Latest Funding Round: Series B, May 06, 2026, $*****
- Highlight: Editors' Pick
Developer of small-molecule drugs for the treatment of cancer. The company utilizes its proprietary Chemoproteomics platform, IMTAC that enables the screening of small molecules against all the proteins in live cells to discover drug candidates for high value and hard-to-drug targets that cause diseases.
Key facts about BridGene Biosciences
- Founded Year: 2018
- Location: Sunnyvale (United States)
- Stage: Series B
- Total Funding till date: $78.5M
- Employee Count: 31 as on May 31, 2026
- Investors: GTJAI, ShenZhen GTJA Investment Group and 8 Others
- Latest Funding Round: Series B, Oct 16, 2025, $*****
- Highlight: Editors' Pick
Developer of RNA-based therapeutics for multiple diseases. The company is leveraging machine learning technology and innovative RNA techniques to develop medicines for the treatment of cancer, rare genetic disorders, and infectious diseases.
Key facts about ReviR Therapeutics
- Founded Year: 2021
- Location: San Francisco (United States)
- Stage: Series A
- Total Funding till date: $54M
- Employee Count: 21 as on May 31, 2026
- Investors: State of California, Shunwei Capital and 8 Others
- Latest Funding Round: Series A, Apr 21, 2026, $*****
- Highlight: Editors' Pick
Developer of gene editing therapies for a wide variety of diseases. The company uses proprietary and patented technology platform Artificial intelligence (AI) algorithms and lipid nanoparticle (LNP) medicine delivery system to deliver medicine to target cells and tissues ex vivo and in vivo in ocular, neurodegeneration, metabolic, and rare disease models.
Key facts about Epigenic Therapeutics
- Founded Year: 2021
- Location: Shanghai (China)
- Stage: Series B
- Total Funding till date: $112M
- Employee Count: 17 as on May 31, 2026
- Investors: Orbimed, Qiming Venture Partners and 6 Others
- Latest Funding Round: Series B, Sep 07, 2025, $*****
- Highlight: Editors' Pick
Lapam Capital's Year-on-Year Investment Trends
Lapam Capital has invested in 19 companies over the last 13 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 8 investments, while as of May 2026, it has made 1 investment in this year. Its most recent first time investment was in Degron Therapeutics and most recent follow-on round was in BridGene Biosciences.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 0 | 1 |
2025 | 6 | 2 | 8 |
2024 | 3 | 0 | 3 |
2023 | 0 | 0 | 0 |
2022 | 4 | 0 | 4 |
2021 | 2 | 0 | 2 |
2020 | 1 | 0 | 1 |
2019 | 0 | 0 | 0 |
2018 | 0 | 0 | 0 |
2017 | 1 | 0 | 1 |
Lapam Capital's Investments by Stage
Lapam Capital has made 7 investments in Series A stage with an average round size of $29.3M, 6 investments in Series B stage with an average round size of $52.8M, 3 investments in Seed stage with an average round size of $40M and 3 investments in Series C stage with an average round size of $47.4M.Stage of entry | No. of Investments |
|---|---|
Series A | 7 |
Series B | 6 |
Seed | 3 |
Series C | 3 |
Note: We have considered here, only first round of investments
Lapam Capital's Investments by Sector
Lapam Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Healthcare, HealthTech and Sustainability Tech. Notably, it has invested in 17 Tech companies, 16 Enterprise (B2B) companies and 1 Tech hardware company.Sector | No. of Investments |
|---|---|
Life Sciences | 17 |
High Tech | 3 |
Healthcare | 2 |
HealthTech | 1 |
Sustainability Tech | 1 |
Note: We have considered here, only first round of investments
Lapam Capital's Investments by Geography
Lapam Capital has made most investments in China (12), followed by United States where it has made 7 investments.Country | No. of Investments |
|---|---|
China | 12 |
United States | 7 |
Note: We have considered here, only first round of investments
Lapam Capital's recent investments
Lapam Capital has made 1 investments in 2026 so far - Degron Therapeutics.Here are the most recent investments by Lapam Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 14, 2026 | China | Series A | 2450 | ||
Dec 18, 2025 | China | Series A | 6809 | [+1] | |
Dec 16, 2025 | China | Series A | 6448 | [+5] | |
Nov 25, 2025 | China | Seed | 3970 | [+8] | |
Oct 16, 2025 | United States | Series B | 3278 | [+3] |
IPOs and Publicly Listed companies in Lapam Capital's Portfolio
1 of Lapam Capital's portfolio company became public - Suzhou Connect Biopharmaceuticals. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Mar 2021 at marketcap of $949MHere are Lapam Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 19, 2021 | Jan 24, 2017 | Series A | 1078 |
Team profile of Lapam Capital
Lapam Capital has a team of 1 member. Lapam Capital's team does not sit on the board of any company as of now.Co-investors of Lapam Capital
Over the past 13 years, 124 investors have co-invested in Lapam Capital's portfolio companies. This includes only funds.
- Invested before Lapam Capital: Medfine Capital, Sky9 Capital and 44 others have invested in rounds before Lapam Capital. There are 3 companies where Medfine Capital has invested before Lapam Capital and 2 companies where Sky9 Capital has invested before Lapam Capital.
- Top Co-investors of Lapam Capital: 58 investors entered a company along with Lapam Capital. These include investors like Deyi Capital (2 companies).
- Invested after Lapam Capital: A total of 20 investors have invested in Lapam Capital's portfolio after their investments. Top Investors include Vivo Capital (1 company), SK biopharmaceuticals (1 company) and TSG Capital (1 company).
Recent News related to Lapam Capital
•
A Series A, B and an IPO; Cabaletta reports CAR-T resultsEndpoints•May 14, 2026•Degron Therapeutics, Cspc, ApicHope Pharmaceutical, Fortune Capital and 6 others
•
BridGene Biosciences Closes $28M Series B+Massinvestor•Jan 27, 2026•Lapam Capital, GTJAI, BridGene Biosciences, Proxima Ventures and 1 other
•
Rezubio Announces $20 Million Series A Financing to Advance Therapeutics PlatformBenzinga•Dec 19, 2025•Frees Fund, Lapam Capital, Rezubio, RiverHead and 1 other
•
Allink Biotherapeutics Closes $47M Series A Extension for Clinical ProgramsPR Newswire•Dec 16, 2025•Allink Biotherapeutics, Legend Capital, Lapam Capital, Yuanbio Venture Capital and 2 others
•
Phrontline Biopharma Secures $60 Million in Pre-A+ Financing for ADC DevelopmentPR Newswire•Nov 25, 2025•Phrontline Biopharma, Samsung Venture Investment, Sino Biopharmaceutical, Jifeng Ventures and 4 others
•
BridGene Biosciences Raises $28M in Series B+ FundingFinSMEs•Oct 16, 2025•Lapam Capital, GTJAI, BridGene Biosciences, Proxima Ventures and 3 others
•
Full-Life Technologies Announces US$77 Million Financing to Accelerate Radiopharmaceutical DevelopmentPR Newswire•Sep 30, 2025•Junson Capital, Full-Life Technologies, Gordian Ventures, HSG and 5 others
•
•
Rapafusyn Pharmaceuticals Closes $44 Million Series A Financing for Molecular Glue Drug Discovery PlatformAgencia EFE•Sep 04, 2025•Rapafusyn, Yonjin Capital, BioTrack Capital, 3E Bioventures Capital and 5 others
•
EnChannel Medical Raises $82.2M in Series-B FinancingHMP Global Learning Network•May 06, 2025•LAV, EnChannel Medical, Lapam Capital
